Journal ArticleDOI
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890
Christophe Hézode,Hélène Fontaine,Céline Dorival,Dominique Larrey,Fabien Zoulim,Valérie Canva,Victor de Lédinghen,Thierry Poynard,Didier Samuel,Marc Bourlière,Jean-Pierre Zarski,J.-J. Raabe,Laurent Alric,Patrick Marcellin,Ghassan Riachi,Pierre-Henri Bernard,Véronique Loustaud-Ratti,Sophie Metivier,Albert Tran,Lawrence Serfaty,Armand Abergel,Xavier Causse,Vincent Di Martino,Dominique Guyader,Damien Lucidarme,Véronique Grando-Lemaire,Patrick Hillon,Cyrille Feray,Thong Dao,Patrice Cacoub,Isabelle Rosa,Pierre Attali,Ventzislava Petrov-Sanchez,Yoann Barthe,Jean-Michel Pawlotsky,Stanislas Pol,Fabrice Carrat,Jean-Pierre Bronowicki +37 more
Reads0
Chats0
TLDR
The safety profile was poor and patients with platelet count ≤ 100,000/mm(3) and serum albumin <35 g/L should not be treated with the triple therapy, and the on-treatment virological response was high.About:
This article is published in Journal of Hepatology.The article was published on 2013-09-01. It has received 431 citations till now. The article focuses on the topics: Telaprevir.read more
Citations
More filters
Journal ArticleDOI
Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
Nezam H. Afdhal,Stefan Zeuzem,Paul Y. Kwo,Mario Chojkier,Norman Gitlin,Massimo Puoti,Manuel Romero-Gómez,Jean-Pierre Zarski,Kosh Agarwal,Peter Buggisch,Graham R. Foster,Norbert Bräu,Maria Buti,Ira M. Jacobson,G. Mani Subramanian,Xiao Ding,Hongmei Mo,Jenny C. Yang,Phillip S. Pang,William T. Symonds,John G. McHutchison,Andrew J. Muir,Alessandra Mangia,Patrick Marcellin +23 more
TL;DR: Once-daily ledipasvir-sofosbuvir with or without ribavirin for 12 or 24 weeks was highly effective in previously untreated patients with HCV genotype 1 infection.
EASL Clinical Practice Guidelines: Management of hepatitis C virus infection European Association for the Study of the Liver ⇑
TL;DR: The EASL CPGs on the management of HCV infection will be updated on a regular basis upon approval of additional novel therapies, and will apply to therapies that are approved at the time of their publication.
Journal ArticleDOI
ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
Fred Poordad,Christophe Hézode,Roger Trinh,Kris V. Kowdley,Stefan Zeuzem,Kosh Agarwal,Mitchell L. Shiffman,Heiner Wedemeyer,Thomas Berg,Eric M. Yoshida,Xavier Forns,Sandra S. Lovell,Barbara Da Silva-Tillmann,Christine Collins,Campbell Andrew L,Thomas Podsadecki,B. Bernstein +16 more
TL;DR: In this phase 3 trial of an oral, interferon-free regimen evaluated exclusively in patients with HCV genotype 1 infection and cirrhosis, multitargeted therapy with the use of three new antiviral agents and ribavirin resulted in high rates of sustained virology response.
Journal ArticleDOI
EASL Clinical Practice Guidelines: Liver transplantation
Patrizia Burra,Andrew K. Burroughs,Ivo Graziadei,Jacques Pirenne,Juan Carlos Garcia Valdecasas,Paolo Muiesan,Didier Samuel,Xavier Forns +7 more
TL;DR: This Clinical Practice Guideline has been developed to assist physicians and other healthcare providers during the evaluation process of candidates for LT and to help them in the correct management of patients after LT.
Journal ArticleDOI
Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.
Eric Lawitz,Fred Poordad,Phillip S. Pang,Robert H. Hyland,Xiao Ding,Hongmei Mo,William T. Symonds,John G. McHutchison,Fernando E. Membreno +8 more
TL;DR: The findings suggest that the fixed-dose combination of sofosbuvir-ledipasvir alone or with ribavirin has the potential to cure most patients with genotype-1 HCV, irrespective of treatment history or the presence of compensated cirrhosis.
References
More filters
Journal ArticleDOI
Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
Ira M. Jacobson,John G. McHutchison,Geoffrey Dusheiko,Adrian M. Di Bisceglie,K. Rajender Reddy,Natalie Bzowej,Patrick Marcellin,Andrew J. Muir,Peter Ferenci,Robert Flisiak,Jacob George,Mario Rizzetto,Daniel Shouval,Ricard Sola,R. Terg,Eric M. Yoshida,Nathalie Adda,Leif Bengtsson,Abdul J. Sankoh,Tara L. Kieffer,Shelley George,Robert S. Kauffman,Stefan Zeuzem,Vertex Phar +23 more
TL;DR: Telaprevir with peginterferon-ribavirin was associated with significantly improved rates of sustained virologic response in patients with HCV genotype 1 infection who had not received previous treatment, with only 24 weeks of therapy administered in the majority of patients.
Journal ArticleDOI
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
TL;DR: The addition of boceprevir to standard therapy with peginterferon–ribavirin, as com pared with standard therapy alone, significantly increased the rates of sustained virologic response in previously untreated adults with chronic HCV genotype 1 infection.
Journal ArticleDOI
Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
Bruce R. Bacon,Stuart C. Gordon,Eric Lawitz,Patrick Marcellin,John M. Vierling,Stefan Zeuzem,Fred Poordad,Zachary Goodman,Heather L. Sings,Navdeep Boparai,Margaret Burroughs,Clifford A. Brass,Janice K. Albrecht,Rafael Esteban +13 more
TL;DR: The addition of boceprevir to peginterferon-ribavirin resulted in significantly higher rates of sustained virologic response in previously treated patients with chronic HCV genotype 1 infection, as compared with pegintersfer on-off therapy alone.
Journal ArticleDOI
Telaprevir for retreatment of HCV infection.
Stefan Zeuzem,Pietro Andreone,Stanislas Pol,Eric Lawitz,Moisés Diago,Stuart K. Roberts,R. Focaccia,Zobair M. Younossi,Graham R. Foster,Andrzej Horban,Peter Ferenci,Frederik Nevens,Beat Müllhaupt,Paul J. Pockros,R. Terg,Daniel Shouval,Bart van Hoek,Ola Weiland,Rolf van Heeswijk,Sandra De Meyer,Don Luo,G. Boogaerts,Ramon Polo,Gaston Picchio,Maria Beumont +24 more
TL;DR: Telaprevir combined with peginterferon plus ribavirin significantly improved rates of sustained virologic response in patients with previously treated HCV infection, regardless of whether there was a lead-in phase.
Journal ArticleDOI
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.
Adriaan J. van der Meer,Bart J. Veldt,Jordan J. Feld,Heiner Wedemeyer,Jean-François Dufour,Frank Lammert,Andres Duarte-Rojo,E. Jenny Heathcote,Michael P. Manns,L. Kuske,Stefan Zeuzem,W. Peter Hofmann,Robert J. de Knegt,Bettina E. Hansen,Harry L.A. Janssen +14 more
TL;DR: Among patients with chronic HCV infection and advanced hepatic fibrosis, sustained virological response to interferon-based treatment was associated with lower all-cause mortality.
Related Papers (5)
Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
Ira M. Jacobson,John G. McHutchison,Geoffrey Dusheiko,Adrian M. Di Bisceglie,K. Rajender Reddy,Natalie Bzowej,Patrick Marcellin,Andrew J. Muir,Peter Ferenci,Robert Flisiak,Jacob George,Mario Rizzetto,Daniel Shouval,Ricard Sola,R. Terg,Eric M. Yoshida,Nathalie Adda,Leif Bengtsson,Abdul J. Sankoh,Tara L. Kieffer,Shelley George,Robert S. Kauffman,Stefan Zeuzem,Vertex Phar +23 more
Telaprevir for retreatment of HCV infection.
Stefan Zeuzem,Pietro Andreone,Stanislas Pol,Eric Lawitz,Moisés Diago,Stuart K. Roberts,R. Focaccia,Zobair M. Younossi,Graham R. Foster,Andrzej Horban,Peter Ferenci,Frederik Nevens,Beat Müllhaupt,Paul J. Pockros,R. Terg,Daniel Shouval,Bart van Hoek,Ola Weiland,Rolf van Heeswijk,Sandra De Meyer,Don Luo,G. Boogaerts,Ramon Polo,Gaston Picchio,Maria Beumont +24 more
Sofosbuvir for previously untreated chronic hepatitis C infection
Eric Lawitz,Alessandra Mangia,David L. Wyles,Maribel Rodriguez-Torres,Tarek Hassanein,Stuart C. Gordon,Michael Schultz,M. Davis,Zeid Kayali,K. Rajender Reddy,Ira M. Jacobson,Kris V. Kowdley,L. Nyberg,G. Mani Subramanian,Robert H. Hyland,Sarah Arterburn,Deyuan Jiang,John McNally,Diana M. Brainard,William T. Symonds,John G. McHutchison,Aasim Sheikh,Zobair M. Younossi,Edward Gane +23 more